Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between 50 and 85 years of age with a diagnosis of probable Alzheimers Disease,~* Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,~* A primary caregiver willing to accept responsibility for supervising treatment, assessing the patient's condition throughout the study, and for providing input into efficacy assessments.~* For double blind only: Meet the decline criteria of functional (as assessed by the investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State Examination) score between visits or a 3 point reduction from baseline) decline at weeks 23, 36 or 48.~Exclusion Criteria:~* Presence of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments or put the patient at particular risk,~* Any medical or neurological condition other than Alzheimers Disease that could explain the patient's dementia,~* A diagnosis of probable or possible vascular dementia,~* A current diagnosis of unsuccessfully-treated depression, or any other mental disorder that may interfere with the evaluation of the patient's response to study medication,~* A history or current diagnosis of cerebrovascular disease (e.g. stroke),~* A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable coronary artery disease).~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Open label: Rivastigmine (5 cm^2 / 10 cm^2) (Type: EXPERIMENTAL): Rivastigmine 5 cm\^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm\^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
- Double blind: Rivastigmine (10 cm^2) (Type: EXPERIMENTAL): Rivastigmine transdermal patch 10 cm\^2 and placebo to rivastigmine 15 cm\^2 once daily for 48 weeks during the double blind period.
- Double blind: Rivastigmine (15 cm^2) (Type: EXPERIMENTAL): Rivastigmine transdermal patch 15 cm\^2 and placebo to rivastigmine 10 cm\^2 once daily for 48 weeks during double blind period.
- Extended open label Rivastigmine (10 cm^2) (Type: EXPERIMENTAL): Rivastigmine 10 cm\^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.

Based on this trial design, predict the completion outcome and termination type (if applicable).